Biofrontera Total Assets from 2010 to 2024
| BFRI Stock | USD 1.19 0.04 3.48% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 27.9 M | Current Value 40.7 M | Quarterly Volatility 8.7 M |
Check Biofrontera financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biofrontera's main balance sheet or income statement drivers, such as Tax Provision of 33 K, Interest Income of 90.6 K or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 0.12, Dividend Yield of 0.0 or PTB Ratio of 0.85. Biofrontera financial statements analysis is a perfect complement when working with Biofrontera Valuation or Volatility modules.
Biofrontera | Total Assets |
Latest Biofrontera's Total Assets Growth Pattern
Below is the plot of the Total Assets of Biofrontera over the last few years. Total assets refers to the total amount of Biofrontera assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Biofrontera books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Biofrontera's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biofrontera's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 27.93 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Biofrontera Total Assets Regression Statistics
| Arithmetic Mean | 32,291,767 | |
| Geometric Mean | 31,417,383 | |
| Coefficient Of Variation | 27.01 | |
| Mean Deviation | 6,388,160 | |
| Median | 28,752,000 | |
| Standard Deviation | 8,721,207 | |
| Sample Variance | 76.1T | |
| Range | 29.1M | |
| R-Value | 0.50 | |
| Mean Square Error | 61.4T | |
| R-Squared | 0.25 | |
| Significance | 0.06 | |
| Slope | 976,023 | |
| Total Sum of Squares | 1064.8T |
Biofrontera Total Assets History
Other Fundumenentals of Biofrontera
Biofrontera Total Assets component correlations
Click cells to compare fundamentals
About Biofrontera Financial Statements
Investors use fundamental indicators, such as Biofrontera's Total Assets, to determine how well the company is positioned to perform in the future. Although Biofrontera's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Total Assets | 27.9 M | 40.7 M | |
| Intangibles To Total Assets | 0.09 | 0.12 |
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out the analysis of Biofrontera Correlation against competitors. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.16 | Revenue Per Share 11.573 | Quarterly Revenue Growth 0.34 | Return On Assets (0.40) | Return On Equity (1.49) |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.